T2	Participants 273 323	lower compliance and response to antiviral therapy
T3	Participants 411 416	IVDUs
T4	Participants 431 440	non-IVDUs
T5	Participants 593 656	406 previously untreated CHC patients, including 98 (24%) IVDUs
T6	Participants 1637 1664	active and non-active IVDUs
T7	Participants 1676 1735	IVDU patients in or without a methadone maintenance program
T8	Participants 1766 1782	Benelux patients
T9	Participants 1892 1919	patients with CHC infection
T10	Participants 1985 2039	chronic hepatitis C patients who use intravenous drugs
T1	Participants 191 252	intravenous drug users (IVDUs) with chronic hepatitis C (CHC)
T11	Participants 855 876	at the end of therapy
T13	Participants 981 997	non-IVDUs (6.8%)
T12	Participants 927 957	Non-compliance (8.2%) in IVDUs
T14	Participants 1377 1451	sustained virological response between IVDUs (46.6%) and non-IVDUs (34.6%)
